Monday, October 5, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 25, 2026

3 Market Trends That Could Shape the Rest of 2026

View original at finance.yahoo.com
3 Market Trends That Could Shape the Rest of 2026 The past few years have featured pretty much just one dominant market theme: artificial intelligence (AI)…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The S&P 500 has already fallen 9% and rebounded 12% in just the past couple of months, demonstrating that investors are still trying to get a handle on what to expect

    60% confidence
  • A swift resolution to the Middle East conflict could bring inflation back down and reopen the door for Federal Reserve rate cuts

    60% confidence
  • March 2026 inflation came in at 3.3% year over year, much above February's 2.4%

    60% confidence
  • The Iran war has turned inflation expectations upside down, with the March 2026 inflation rate shooting up to 3.3%

    60% confidence
  • Earlier in 2026, the US unemployment rate was 4%-5% and the economy was growing at a healthy clip, supporting the case for rate cuts

    60% confidence
  • An inflation rate in the 3%-4% range makes it very difficult for the Fed to cut rates even if the economy begins slowing more rapidly

    60% confidence
  • Stock prices historically have rebounded strongly once the midterm election has passed

    60% confidence
  • The VIX briefly hit the 30s in 2026 but volatility has since moderated, which could reduce the potential for above-average returns going forward

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,340 source documents archived
Query this data → isubstrate.com